Mack John Prosper Buys Shares of OBIO
Mack John Prosper purchased 34,653 shares of OBIO, reflecting insider confidence.
Key Points
- Mack John Prosper bought 34,653 shares of OBIO on June 23, 2026, as part of insider trading activities.
- OBIO shares traded near $3.98 on Friday, with notable institutional interest from funds like Vanguard Capital Management.
- Analysts from firms like Barclays and HC Wainwright maintain a 'buy' rating, with price targets up to $20.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mack John Prosper recently bought 34,653 shares of OBIO on June 23, 2026. This insider purchase is part of his trading activities and shows potential confidence in the company. Notably, the transaction was not conducted under a prearranged trading plan.
Other Institutional Activity in OBIO
RTW Investments, LP held steady with 8,306,063 shares valued at about $35.3 million. Perceptive Advisors LLC reduced its stake by 89,350 shares, ending with 5,037,906 shares worth approximately $21.4 million, marking a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 2,204,319 shares, valued at around $9.37 million. Propel Bio Management, LLC also initiated a new stake with 896,701 shares, valued at about $3.83 million. Millennium Management LLC significantly boosted its holdings by 459,070 shares, resulting in a 188.6% increase, totaling 702,543 shares worth about $2.99 million.
Orchestra BioMed Holdings, Inc. Stock Down 23.2%
Shares of OBIO traded near $3.98 on Friday. The stock has seen various institutional movements, indicating a dynamic interest in its performance. While specific financial metrics such as market cap and P/E ratio are not available, the trading activity highlights ongoing investor engagement.
$OBIO stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
On June 23, 2026, Mack John Prosper bought 34,653 shares, reflecting a positive insider sentiment. Other insiders, including Eric Fain and Jason Aryeh, were also active, with Fain purchasing 17,327 shares and Aryeh buying 42,553 shares on the same day. These transactions were not part of any prearranged plans, suggesting a direct vote of confidence in OBIO's prospects.
Analysts Set New Price Targets
On May 19, 2026, B. Riley Securities maintained a 'buy' rating on OBIO with a price target of $10. Similarly, HC Wainwright & Co. reiterated its 'buy' rating on May 14, 2026, also with a $10 target. Barclays maintained its 'buy' rating with a target of $13 on May 13, 2026. These consistent 'buy' ratings indicate a strong belief in OBIO's potential upside.
Bottom Line
Mack John Prosper's recent purchase of OBIO shares is a notable insider activity, suggesting confidence in the company's future. Institutional investors and analysts are actively engaging with OBIO, reflecting a broader interest in its performance. Remember, insider trades are reported after the fact and may not represent current positions.
Get Orchestra BioMed Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.